Template:KDRG: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 22: | Line 22: | ||
#[[Nirogacestat]] | #[[Nirogacestat]] | ||
#[[Nedosiran]] | #[[Nedosiran]] | ||
#[[Ryzneuta]] | |||
#[[Endocarditis overview]] | |||
#[[Sparsentan]] | |||
#[[BRENZAVVY- bexagliflozin]] | |||
#[[New GOLD 2024 Recommendation for Vaccination of COPD Patients]] | |||
#[[Nirsevimab]] | |||
#[[Xacduro- sulbactam and durlobactam]] | |||
#[[EXXUA]] | |||
#[[Somatrogon-ghla]] | |||
#[[Chronic renal failure overview]] | |||
#[[Aprocitentan]] | |||
Revision as of 02:01, 23 May 2024
Kosar Doraghi, M.D.
Current Position
Associate Editor-in-Chief, Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar
Pages Authored/Co-authored/Collaborated
- NEXOBRID
- RELYVRIO
- Deucravacitinib
- Ublituximab-xiiy
- futibatinib
- Tapinarof
- Spevigo- spesolimab-sbz
- Vericiguat
- Dasiglucagon
- Ponesimod
- Lasmiditan
- Nirogacestat
- Nedosiran
- Ryzneuta
- Endocarditis overview
- Sparsentan
- BRENZAVVY- bexagliflozin
- New GOLD 2024 Recommendation for Vaccination of COPD Patients
- Nirsevimab
- Xacduro- sulbactam and durlobactam
- EXXUA
- Somatrogon-ghla
- Chronic renal failure overview
- Aprocitentan